Inj, ado-trastuzumab emt 1mg
Products billed under this code include Kadcyla.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Kadcyla.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Kadcyla | Genentech, Inc. | 50242-0087-01 | 160 | $7,017.60 |
| Kadcyla | Genentech, Inc. | 50242-0088-01 | 100 | $4,386.00 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $43.86 | +$0.234 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted September 17, 2026 |
| 3Q26 | $43.626 | +$1.428 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted September 15, 2026 |
| 2Q26 | $42.198 | +$0.005 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted September 15, 2026 |
| 1Q26 | $42.193 | +$0.033 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted September 15, 2026 |
| 4Q25 | $42.16 | +$0.306 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted September 8, 2026 |
| 3Q25 | $41.854 | +$0.749 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted March 10, 2026 |
| 2Q25 | $41.105 | +$0.137 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted March 10, 2026 |
| 1Q25 | $40.968 | +$0.523 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted December 19, 2025 |
| 4Q24 | $40.445 | +$0.403 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted June 11, 2025 |
| 3Q24 | $40.042 | +$1.604 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted June 11, 2025 |
| 2Q24 | $38.438 | +$0.07 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted March 11, 2025 |
| 1Q24 | $38.368 | +$0.029 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted December 19, 2024 |
| 4Q23 | $38.339 | +$0.014 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted October 10, 2024 |
| 3Q23 | $38.325 | +$2.08 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted June 5, 2024 |
| 2Q23 | $36.245 | −$0.025 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted February 23, 2024 |
| 1Q23 | $36.27 | +$0.575 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted December 6, 2023 |
| 4Q22 | $35.695 | +$0.079 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted June 22, 2023 |
| 3Q22 | $35.616 | +$1.477 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted June 9, 2023 |
| 2Q22 | $34.139 | −$0.012 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted December 14, 2022 |
| 1Q22 | $34.151 | −$0.033 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted June 8, 2022 |
| 4Q21 | $34.184 | +$0.029 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted June 2, 2022 |
| 3Q21 | $34.155 | +$1.256 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted June 2, 2022 |
| 2Q21 | $32.899 | +$0.052 | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted March 1, 2022 |
| 1Q21 | $32.847 | – | 1 MG | Inj, ado-trastuzumab emt 1mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.